Drug Combination Details

General Information of the Combination (ID: C90689)
Name Mycophenolate mofetil   NP Info  + Losartan   Drug Info 
Structure +
Disease
Immunoglobulin A nephropathy [ICD-11: MF8Y]
Clinical trial [1]
Chronic cyclosporine nephropathy [ICD-11: GB55]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Decreasing Adverse Drug Reaction by This Combination
                 Decreasing Adverse Drug Reaction     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation		 Up-regulation Expression AGTRAP  Molecule Info 
Pathway MAP
                    In-vivo Model Male Sprague-Dawley rats, weighing 225 to 250 g were used in this study.
                    Experimental
                    Result(s)		 MMF treatment decreases CsA-induced nephrotoxicity, and combined treatment with LSRT has a synergistic effect in preventing chronic CsA nephrotoxicity.
References
Reference 1 ClinicalTrials.gov (NCT01854814) The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients (MAIN).
Reference 2 Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Transplantation. 2003 Feb 15;75(3):309-15.
 Download Picture         KEGG Link